ADCs, including Adcentris® (Seattle Genetics) [86] and Kadcyla® (Genentech)[87], have received FDA approval for targeted treatment of relapsed Hodgkin Lymphoma and Her-2 positive breast cancer, respectively. Here, ERBB2 is linked to breast cancer.